HCPCS Level II code J3316 identifies the extended-release injectable formulation of triptorelin, 3.75 mg. Triptorelin is a GnRH agonist used for medical suppression of gonadal steroid production in a range of clinical indications; the HCPCS designation signals billing for the drug as a separately payable J‑code. Nationally, accurate use of J3316 affects drug utilization reporting, payer coverage determinations, and facility billing workflows for outpatient injectable therapies.

This analysis covers common national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how the code is used clinically and administratively, typical sites of service, and which payers are included in the coverage review. The publication also summarizes available benchmarks and policy considerations relevant to outpatient administration of depot GnRH agonists and highlights any recent policy updates or common billing considerations where applicable.

The report is intended to inform revenue cycle teams, clinicians who administer depot injections, and policy analysts about code purpose, payer coverage landscape, and areas to monitor for reimbursement or policy change. Data not available in the input will be noted where appropriate.